BTP 114

Drug Profile

BTP 114

Alternative Names: BTP-114

Latest Information Update: 14 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tarveda Therapeutics
  • Developer Placon Therapeutics
  • Class Antineoplastics; Drug conjugates; Platinum complexes
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02950064)
  • 01 Feb 2016 BTP 114 is available for licensing as of 27 Jan 2016.
  • 27 Jan 2016 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top